What will happen when the best selling drug ever finally faces direct competition?

DONATE

Reporting on complex health policy issues is no easy task. By supporting Tradeoffs, you help make our ambitious storytelling, relentless fact finding, and rigorous research possible.

Tradeoffs (EIN: 834075323) is a 501(c)(3) organization.

RECENT STORIES

Explore all of our episodes

The End of Humira’s $200 Billion Drug Monopoly

What will happen when the best selling drug ever finally faces direct competition?

Read More

Three Health Policy Stories to Watch in 2023

In 2023, states will pursue new abortion laws, restart Medicaid eligibility checks and Medicare will begin to flex its new power to negotiate drug prices.

Read More

Best Health Care Podcasts of 2022

Our annual look back at some of the best health care podcast episodes of the year with help from a few of our podcast host friends.

Read More

As Featured In: